November Guidelines Banner Image
  • Malaria
    • Society:World Health Organization (WHO)
    • Published:November 25, 2022

COPD Clinical Guidelines Roundup for #WorldCOPDDay 2022

November Drug Approvals Banner Image
  • Vemlidy (Gilead)
    • Expanded indication to children aged 12 years and older with chronic hepatitis B virus (HBV) infection with compensated liver disease.
  • Libtayo (Sanofi / Regeneron)
    • In combination with platinum-based chemotherapy for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with no EGFR, ALK or ROS1 aberrations.
  • Imjudo + Imfinzi (AstraZeneca)
    • Treatment of adult patients with Stage IV (metastatic) non-small cell lung cancer (NSCLC).
  • Adcetris (Seagen)
    • Treatment of pediatric patients 2 years and older with previously untreated high risk classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide.
  • Elahere (ImmunoGen)
    • Treatment of adult patients with folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens.
  • Liletta (Medicines360)
    • To prevent pregnancy for up to eight years.
  • Tzield (Provention Bio)
    • To delay the onset of clinical type 1 diabetes in people aged 8 years and older who are at high risk for developing the condition.
  • Rezvoglar (Eli Lilly)
    • To improve glycemic control in adults and pediatric patients with diabetes mellitus.
  • Sezaby (Sun Pharma)
    • Treatment of neonatal seizures.
  • Hemgenix (CSL Behring)
    • Treatment of adults with Hemophilia B (congenital Factor IX deficiency).
  • Rebyota (Ferring Pharmaceuticals)
    • To prevent recurrence of Clostridioides difficile infection (CDI) in people aged 18 years and older.

What’s New in Clinical Guidelines for #NationalDiabetesMonth

Copyright © 2022 Guideline Central, All rights reserved.